Comparison between single-agent and combination chemotherapy as second-line treatment for advanced non-small cell lung cancer: a multi-institutional retrospective analysis.

Cancer Chemotherapy and Pharmacology
Yanjiao YiBao Song

Abstract

Doublet combination chemotherapy is commonly considered a second-line treatment for advanced non-small cell lung cancer (NSCLC) in China. This multi-institutional retrospective analysis evaluated and compared the efficacy between combination and mono-therapy after platinum-based first-line chemotherapy in Chinese patients with advanced NSCLC. We retrospectively reviewed 335 patients who received second-line chemotherapy for advanced NSCLC. The primary endpoint was overall survival (OS), and the secondary endpoints were progression-free survival (PFS), response rate (RR) and toxicity. Treatment-free interval (TFI) was used for further stratification analysis. The Cox proportional hazards model was used for multivariate analysis. Two hundred and fifty-three patients received doublet combination chemotherapy and 82 received single-agent chemotherapy. PFS was significantly prolonged in combination group compared to single-agent group (median 5.70 vs 3.70 months; HR 0.62; 95% CI 0.45-0.85; p < 0.001). The RR was significantly higher in the combination group than in the single-agent group (29.25% vs. 10.98%; p = 0.001). OS was also prolonged in combination group versus single-agent group (median 13.30 vs. 11.45 months, respectively; ...Continue Reading

References

May 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F A ShepherdJ Berille
Jan 11, 2002·The New England Journal of Medicine·Joan H SchillerUNKNOWN Eastern Cooperative Oncology Group
May 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nasser HannaPaul A Bunn
Jul 29, 2004·JAMA : the Journal of the American Medical Association·Catherine DelbaldoJean-Pierre Pignon
Dec 31, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rogerio C LilenbaumMark R Green
Jan 26, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D PectasidesS A Raptis
Jul 15, 2005·The New England Journal of Medicine·Frances A ShepherdUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Dec 15, 2006·The New England Journal of Medicine·Alan SandlerDavid H Johnson
Jul 18, 2008·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Vittorio GebbiaAlessandro Morabito
Feb 4, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martin ReckChristian Manegold
Mar 11, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Massimo Di MaioCesare Gridelli
Mar 25, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Egbert F SmitHarry J M Groen
Apr 8, 2009·Proceedings of the American Thoracic Society·Thomas E Stinchcombe, Mark A Socinski
Aug 21, 2009·The New England Journal of Medicine·Tony S MokMasahiro Fukuoka
Nov 18, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christopher G AzzoliUNKNOWN American Society of Clinical Oncology
Jan 15, 2010·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Tatsuya NaganoYutaka Nishiwaki
Jan 13, 2012·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal
Jan 31, 2012·The Lancet Oncology·Rafael RosellUNKNOWN Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia T
Jul 3, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lecia V SequistMartin Schuler
Jan 9, 2014·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal
Dec 10, 2014·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Yong Won ChoiSoon Young Lee
Sep 2, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gregory A MastersUNKNOWN American Society of Clinical Oncology Clinical Practice

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.